Tracking Immune Activation by Stress Proteins In Vivo

体内应激蛋白追踪免疫激活

• 批准号: 7036312
• 负责人: CHRISTOPHER A PENNELL
• 金额: $ 25.68万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7036312
• 关键词: memory; stress proteins

DESCRIPTION (provided by applicant): Vaccines containing peptides linked to stress proteins are the most potent known T cell immunogens. However, the precise mechanisms by which they activate immune cells remain unclear. To address this, we will track activated dendritic cells (DCs) and CD8+ T cells in mice immunized with antigens fused to the stress protein hsp70, and determine which cytokines and cell surface receptors are required for their responses. Our preliminary studies reveal hspTO fusion vaccines elicit much more potent and durable specific CD8+ T cell responses than antigen alone or with other adjuvants. Our underlying hypothesis is that antigen/hsp70 fusions are potent vaccines because they stimulate DCs to provide an optimal microenvironment for CD8+ T cell activation. This microenvironment is defined by high antigen density and strong costimulation. To test this, we will track in vivo DC and CD8+ T cell responses in draining lymph nodes, and the resultant effector and memory CD8+ T lymphocytes in the periphery. Novel aspects of our proposal include: 1) quantifying the amount of antigen presented by activated DCs, 2) the effect hsp70 fusion proteins have on DC lifespan, 3) determining which of the several reported hsp70-receptors are necessary or sufficient for delivering activation signals to DCs in vivo, and 4) determining the costimulatory and cytokines required for the profound effect our vaccine has CD8+ T cell memory. The results of these experiments will allow us to manipulate stress protein-induced responses rationally with the ultimate goal of maximizing their use for cancer therapy.

描述（由申请人提供）：含有与应力蛋白相关的肽的疫苗是最有效的已知T细胞免疫原子。但是，它们激活免疫细胞的确切机制尚不清楚。为了解决这个问题，我们将跟踪活化的树突状细胞（DCS）和CD8+ T细胞，用融合到应激蛋白HSP70的抗原免疫的小鼠中，并确定其反应需要哪些细胞因子和细胞表面受体。我们的初步研究表明，HSPTO融合疫苗比单独或与其他佐剂相比，引起更有效和耐用的特异性CD8+ T细胞反应。我们的基本假设是抗原/HSP70融合是有效的疫苗，因为它们刺激DC为CD8+ T细胞激活提供最佳的微环境。这种微环境由高抗原密度和强烈的共刺激来定义。为了测试这一点，我们将在排水淋巴结中跟踪体内DC和CD8+ T细胞反应，以及所得的效应子和周围的记忆CD8+ T淋巴细胞。 Novel aspects of our proposal include: 1) quantifying the amount of antigen presented by activated DCs, 2) the effect hsp70 fusion proteins have on DC lifespan, 3) determining which of the several reported hsp70-receptors are necessary or sufficient for delivering activation signals to DCs in vivo, and 4) determining the costimulatory and cytokines required for the profound effect our vaccine has CD8+ T cell 记忆。这些实验的结果将使我们能够合理地操纵应激蛋白诱导的反应，以最大程度地提高其用于癌症治疗的最终目标。